

Valera Pharmaceuticals Inc  
Form 8-K  
February 22, 2007

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**FORM 8-K**  
**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

February 22, 2007

Date of Report (Date of earliest event reported)

**VALERA PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-51768**  
(Commission File Number)

**13-4119931**  
(IRS Employer  
Identification No.)

**7 Clarke Drive**  
**Cranbury, New Jersey**  
(Address of principal executive offices)

**(609) 235-3000**

**08512**  
(Zip Code)

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

## Edgar Filing: Valera Pharmaceuticals Inc - Form 8-K

- “ Soliciting materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13-4(c))
-

**Item 2.02. Results of Operations and Financial Condition.**

Valera Pharmaceuticals, Inc. (the **Company** ) today issued a press release reporting the Company's financial results for the quarterly period and year ended December 31, 2006. The press release also sets forth the Company's progress with respect to certain product milestones and identifies recent developments affecting the Company.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d)	Exhibit No.	Description
	99.1	Press Release issued February 22, 2007.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**VALERA PHARMACEUTICALS, INC.**

Date: February 22, 2007

By: /s/ Andrew T. Drechsler  
Andrew T. Drechsler

Chief Financial Officer

**Index of Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
99.1*	Press Release issued February 22, 2007.

---

\* Filed herewith